1292289-46-3

Basic information

• Product Name: (S)-4-(AMinoMethyl)pyrrolidin-2-one
• Synonyms: (S)-4-(AMinoMethyl)pyrrolidin-2-one;(4S)-4-(aminomethyl)pyrrolidin-2-one;(S)-4-(1-aminomethyl)pyrrolidine-2-one
• CAS NO: 1292289-46-3
• Molecular Formula: C₅H₁₀N₂O
• Molecular Weight: 114.1457
• EINECS: -0
• Mol File: 1292289-46-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-4-(AMinoMethyl)pyrrolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(AMinoMethyl)pyrrolidin-2-one(1292289-46-3)
• EPA Substance Registry System: (S)-4-(AMinoMethyl)pyrrolidin-2-one(1292289-46-3)

Safety Data

• Hazardous Substances Data: 1292289-46-3(Hazardous Substances Data)

Usage

General Description

(S)-4-(Aminomethyl)pyrrolidin-2-one, also known as S-AMPO, is a chemical compound that is commonly used as a chiral building block in organic synthesis. It is a cyclic, five-membered amine with an amino group attached to the second carbon of the pyrrolidinone ring. S-AMPO is often used as a reagent in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. It is known for its ability to contribute to the stereochemical control of reactions and is widely used in the pharmaceutical industry for the production of chiral drug molecules. Additionally, S-AMPO has been studied for potential applications in catalysis and material science due to its unique structural and chemical properties.

Upstream product

• 173340-22-2 (4S)-4-(aminomethyl)-1-[(1R)-1-phenylethyl]pyrrolidin-2-one 
• 97-65-4 2-methylenesuccinic acid 
• 99735-43-0 (3R)-1-((R)-1-phenylethyl)-5-oxo-3-pyrrolidinecarboxylic acid 
• 1292289-47-4 (3R)-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carbonitrile 
• 173340-21-1 (3R)-5-oxo-1-[(1R)-1-phenylethyl]pyrrolidine-3-carboxamide 
• 190957-22-3 (4R,1'R)-1-(1'-phenylethyl)-4-hydroxymethylpyrrolidin-2-one 
• 1319736-72-5 C₂₁H₁₆Cl₄N₂O₃ 
• 1319736-73-6 C₁₃H₈Cl₄N₂O₃ 

Downstream Products

• 1319738-00-5 (S)-4-((7-(3,4,5-trimethoxyphenyl)-1,6-naphthyridine-5-ylamino)methyl)pyrrolidine-2-one 

Relevant articles and documents

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among —O—R3 or —NR3R4,R3 is C1-6-alkyl which is substituted by R5 and R6,R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, —C1-6-alkylen-O—C1-3-alkyl, C1-3-haloalkyl,R6 is ring X wherein n is either 0 or 1, and is a either a single or a double bond andwherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, —C1-3-alkyl, —C1-3-haloalkyl, —O—C1-3-alkyl, —C1-3-alkanol and halogen,and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.

SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS

The invention relates to new substituted naphthyridines of formula (1), as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein R1 is selected from among -O-R3 or -NR3R4, R3 is C1-6-alkyl which is substituted by R5 and R6 R5 is selected from hydrogen, branched or linear C1-6-alkyl, C2-6-alkenyl, -C1-6-alkylen-O-C1-3-alkyl, C1-3-haloalkyl, R6 is ring X wherein n is either 0 or 1, and Formula (I) is a either a single or a double bond and wherein A, B, D and E are each independently from one another selected from CH2, CH, C, N, NH, O or S and wherein ring X is attached to the molecule either via position A, B, D or E, wherein said ring X may optionally be further substituted by one, two or three residues each selected individually from the group consisting of -oxo, hydroxy, -C1-3-alkyl, -C1-3-haloalkyl, -O-C1-3-alkyl, -C1-3-alkanol and halogen, and wherein R4, R2, R7, R8, R9, R10, R11 and Q may have the meanings as given in claim 1, as well as pharmaceutical compositions containing these compounds.